June 24, 2020 / 2:53 PM / in 9 days

BRIEF-Relief Therapeutics And NeuroRx Announce FDA's Accelerated Designation Of RLF-100

June 24 (Reuters) - RELIEF THERAPEUTICS HOLDING SA:

* NEURORX AND RELIEF THERAPEUTICS ANNOUNCE FDA’S ACCELERATED DESIGNATION OF RLF-100 (AVIPTADIL) FOR THE TREATMENT OF RESPIRATORY DISTRESS IN COVID-19

* AT THE REQUEST OF THE FDA, NEURORX IS SUBMITTING AN EXPANDED ACCESS POLICY ALLOWING DOCTORS TO REQUEST RLF-100 FOR PATIENTS MEETING THIS CRITERION

* RLF-100 IS UNDERGOING PHASE 2/3 CLINICAL TRIALS

* RECRUITING PATIENTS WITH CRITICAL COVID-19 AND RESPIRATORY FAILURE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below